Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.
Occurrences
Jerry has led efforts to protect the health of mothers in the workplace through his landmark bill, the Pregnant Workers Fairness Act, introduced sweeping legislation to lower exorbitant prescription drug costs, battled extremist efforts to weaken birth control protections, and, of course, has worked tirelessly throughout the entirety of his career to protect women’s reproductive rights, including abortion.
Campaign page says Nadler introduced legislation to lower prescription drug costs.
unverified · Source version 23737 · locator unknown
"Pharmaceutical companies spend billions of dollars on ads that drive up the cost of their already expensive prescription drugs," said Representative Nadler. "The End Prescription Drug Ads Now Act will lower pharmaceutical drug prices for Americans by putting a stop to these wasteful ads..."
Unverified model/legacy excerpt; not proof. AI summary (separate from source): In July 2025, Nadler publicly introduced legislation explicitly intended to lower prescription drug prices by banning prescription drug advertising.
unverified · Source version 23738 · locator unknown
"...the Independent Drug Value Assessment Act will help prevent corporate abuse and ensure that prices reflect the real value of drugs to patients, caregivers, and taxpayers."
Unverified model/legacy excerpt; not proof. AI summary (separate from source): Nadler has consistently sponsored bills aimed at reducing drug prices through pricing oversight and market discipline, showing concrete legislative effort on the issue.
unverified · Source version 23739 · locator unknown
"...the introduction of a new bipartisan legislative package that will enhance efforts to lower prescription drug costs by taking on anticompetitive practices employed by large pharmaceutical companies."
Unverified model/legacy excerpt; not proof. AI summary (separate from source): Nadler previously advanced bipartisan legislation focused on generic-drug access and anti-competitive practices to lower prescription drug costs.
unverified · Source version 23740 · locator unknown
"Today, the House Judiciary Committee unanimously passed four bills to address prescription drug pricing..."
Unverified model/legacy excerpt; not proof. AI summary (separate from source): Nadler helped move multiple drug-pricing bills through committee, a concrete legislative step toward lowering prescription drug costs, though not final enactment shown here.
unverified · Source version 23741 · locator unknown
"...introduced H.R. 2375... which will help lower prescription drug prices for Americans."
Unverified model/legacy excerpt; not proof. AI summary (separate from source): This is an earlier explicit legislative effort by Nadler to reduce drug prices by facilitating lower-cost generics and biosimilars.
unverified · Source version 23742 · locator unknown
"...House Republicans have abandoned their promise to lower costs for working families."
Unverified model/legacy excerpt; not proof. AI summary (separate from source): This shows Nadler continuing to frame lower costs, including health-care-related costs, as an active policy objective late in 2025; it does not prove enactment of a prescription-drug-cost policy.
unverified · Source version 23743 · locator unknown
The report discusses prescription drug pricing reforms and notes savings from reducing the price of drugs such as Humira.
Unverified model/legacy excerpt; not proof. AI summary (separate from source): A House committee report in Nadler’s broader congressional sphere indicates continued federal attention to drug pricing, but it does not show that Nadler’s specific claim was fully delivered in the lookback window.
unverified · Source version 57582 · locator unknown
"The below links contain the MFP explanations for the 10 drugs covered under Medicare Part D that were selected for the first cycle of negotiations; the MFPs will go into effect on January 1, 2026." "Page Last Modified: 09/15/2026 02:47 PM"
Unverified model/legacy excerpt; not proof. AI summary (separate from source): CMS updated its selected-drug negotiated-prices page within the lookback window, showing the Medicare Drug Price Negotiation Program's first-cycle maximum fair prices for 10 Part D drugs with a January 1, 2026 effective date. This is concrete implementation of lower drug prices, but only for selected Medicare drugs, so it supports partial delivery rather than full fulfillment of the broad promise.
Unverified model/legacy excerpt; not proof. AI summary (separate from source): The official House roll call shows Nadler voted yes on H.R. 5376, the Inflation Reduction Act vehicle that passed the House and enabled the Medicare drug-pricing provisions documented by CMS. This documents concrete legislative effort tied to partial delivery of lower prescription drug costs.
Public state: unverifiedAs of unknown · legacy_unverified · . Original AI recommendation (not independently established): partial.same_termA for effort
The evidence shows Nadler repeatedly sponsored and advanced legislation explicitly aimed at lowering prescription drug costs, including generic/biosimilar competition bills, broader bipartisan anti-competitive-practices packages, and later drug-pricing reform proposals. He also helped move multiple bills through the House Judiciary Committee. However, the record provided does not show that Nadler secured final enactment of a policy clearly attributable to him that delivered the promised outcome in full during the relevant period. Because there is substantial documented legislative effort but no clear proof of full delivery, the best judgment is partial fulfillment rather than delivered.